Wednesday, November 1, 2017
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and Bristol-Myers (BMY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
AbbVie's shares have gained +44.1% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +14.6% over the same period. AbbVie reported mixed Q3 results. While earnings beat estimates, revenues came in line. Humira and Imbruvica kept up the strong performance.
Meanwhile, AbbVie raised its earnings outlook for the year backed by a strong year-to-date performance. Despite new competition, it raised its long-term target for Humira sales based on strong demand trends for the drug.
The Zacks analyst stresses that the past 2-3 months have been strong for the company as it presented promising data from several pivotal studies, gained regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settled its Humira patent disputes with Amgen.
Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition.
(You can read the full research report on AbbVie here >>>).
Shares of Buy-rated Union Pacific have outperformed the Zacks Rail Transportation Industry as well as fellow railroad operator Kansas City Southern over the last three months. While the company has gained +13.1%, the industry in belongs to and Kansas City Southern have rallied +8.3% and +2.1%, respectively, so far this year.
Ushering in further good news, Union Pacific reported better-than-expected earnings per share and revenues in the third quarter of 2017. Results were aided by strong performances of the company's intermodal and industrial products units.
The Zacks analyst is impressed by the company's efforts to cut costs to drive its bottom line as well. Efforts to reward investors also raise optimism in the stock. However, declining coal revenues in the third quarter raise concerns. Automotive volumes also decreased due to sluggish vehicle production in the United States.
(You can read the full research report on Union Pacific here >>>).
Strong Buy-rated Bristol-Myers shares have underperformed the broader market as well as the Zacks Large Cap Pharmaceuticals industry this year, gaining only +5.5% in the year-to-date period. Bristol-Myers reported mixed results for the third-quarter with earnings missed expectations although revenue beat on the same. The miss in earnings was attributable to lower gross margin which in turn was due to product mix and decline in virology business.
The Zacks analyst thinks the increase in earnings guidance is encouraging. The company’s blockbuster immuno-oncology Opdivo continues to perform well along with Eliquis and Orencia. The company is looking to expand Opdivo’s label further and recently won FDA approvals for liver and colorectal cancers which should boost performance.
The company is also looking to counter generic threat for its key drugs through deals and acquisitions. The company recently entered into a deal with AbbVie and Halozyme. However, Opdivo is currently facing competitive challenges in the United States. The virology business is also under pressure.
(You can read the full research report on Bristol-Myers here >>>).
Other noteworthy reports we are featuring today include Xilinx (XLNX), Weyerhaeuser (WY) and Colgate (CL).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
AbbVie (ABBV) Gains from Mavyret Approval & Other Updates
Robust Industrial Products Revenues Buoy Union Pacific (UNP)
Strong Opdivo Growth to Boost Bristol-Myers (BMY)'s Top-Line
Strong Box-office Revenues, Cost Cuts Aid IMAX Corp (IMAX)
The Zacks analyst appreciates the company's efforts to check costs. Strong box-office revenues also raise optimism in the stock.
Weyerhaeuser's (WY) Twin Creeks Deal to Help Core Growth
Per the Zacks analyst, Weyerhaeuser can use the proceeds from the sale of its 21% interest in Twin Creeks to develop its core timber, land and forest products business.
Principal's (PFG) Expenses Hurt, Asset Management Strong
Per the Zacks analyst, Principal Financial's increasing expenses weigh on margin expansion.
AbbVie (ABBV) Gains from Mavyret Approval & Other Updates
he Zacks analyst points out that in Q3, AbbVie presented promising data from several pivotal studies, gained approval for HCV medicine Mavyret and settled its Humira patent disputes with Amgen.
Capella (CPLA) Strong on FlexPath Programs, Enrollments Down
Per the Zacks analyst, increased demand for FlexPath programs should drive Capella's top line growth.
IPG Photonics (IPGP) Banks on Solid Adoption of Fiber Lasers
Per the Zacks analyst, IPG Photonics is benefiting from the strong adoption of fiber lasers over conventional lasers and non-laser cutting and welding equipment.
Higher Premiums Aid CNA Financial (CNA), Cat Loss Ails
Per the Zacks analyst, improving premiums continue to boost CNA Financial's revenues, thereby boosting the company's overall growth.
Xilinx (XLNX) Banks on AI, 5G & IoT Technologies for Growth
The Zacks analyst believes that Xilinx is focused on tapping emerging technologies like AI, 5G connectivity, autonomous vehicles and IoTs to drive growth over the long run.
Statoil (STO) to Benefit From Norwegian Upstream Projects
The Zacks analyst expects Statoil to generate significant cash flow from new upstream projects in the Norwegian Continental Shelf.
Hess (HES) to Gain From Offshore Guyana Crude Discoveries
The Zacks analyst believes that world-class discoveries made in the offshore Guyana resources will boost Hess??? crude production.
Higher Costs Remain a Threat to Colgate's (CL) Margins
Per the Zacks analyst, Colgate's margins in third-quarter were hurt by increased raw material and packaging costs, and higher advertising expenses, which are likely to persist and hit margins in 2017.
Weak Margins Irk Omnicell (OMCL) Amid Tough Competition
The Zacks analyst is worried about rising costs from Aesynt and Ateb integration and XT series launch costs. Also, tough competion in the medication & supply chain solutions market is a worry.
Vornado's (VNO) Asset Pruning Moves to Curb Near-Term Growth
Vornado's portfolio pruning efforts are a strategic fit for the long term. However, the earnings dilutive impact cannot be bypassed in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Xilinx, Inc. (XLNX) : Free Stock Analysis Report
Weyerhaeuser Company (WY) : Free Stock Analysis Report
Union Pacific Corporation (UNP) : Free Stock Analysis Report
Colgate-Palmolive Company (CL) : Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research